| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Author Index
|
|
|
|
20 |
S1 |
p. S119-S128
|
artikel
|
| 2 |
EPS1.09 Adapting services during the COVID-19 pandemic – a patient evaluation of physiotherapy telephone reviews within multidisciplinary team virtual clinics
|
Fitzgerald, S.
|
|
|
20 |
S1 |
p. S31
|
artikel
|
| 3 |
EPS1.06 A retrospective audit of home-based spirometry quality in a large UK adult cystic fibrosis centre
|
Waller, I.
|
|
|
20 |
S1 |
p. S30-S31
|
artikel
|
| 4 |
EPS2.05 Arm circumference and skinfolds vs. body mass index: a single-centre experience over two decades
|
Appelt, D.
|
|
|
20 |
S1 |
p. S33
|
artikel
|
| 5 |
EPS1.04 Audit of virtual exercise class during COVID-19 in children with cystic fibrosis
|
Johnstone, Z.
|
|
|
20 |
S1 |
p. S30
|
artikel
|
| 6 |
EPS3.09 Biofilm formation in methicillin-resistant Staphylococcus aureus isolated in cystic fibrosis patients is strain-dependent and differentially influenced by antibiotics
|
Boudet, A.
|
|
|
20 |
S1 |
p. S37
|
artikel
|
| 7 |
EPS3.06 Ceftolozane/tazobactam: a new drug with superior effect against resistant P. aeruginosa
|
Kolpen, M.
|
|
|
20 |
S1 |
p. S36-S37
|
artikel
|
| 8 |
EPS2.02 Characterisation of liver USS findings in pre-school children with cystic fibrosis
|
Keown, K.
|
|
|
20 |
S1 |
p. S32
|
artikel
|
| 9 |
EPS3.10 Clinical pharmacokinetics and dose recommendations for posaconazole gastro-resistant tablets in children with cystic fibrosis
|
Bentley, S.
|
|
|
20 |
S1 |
p. S37-S38
|
artikel
|
| 10 |
EPS3.04 Depolarisation of the Pseudomonas aeruginosa cytoplasmic membrane by Glatiramer acetate potentiates the antibacterial activity of tobramycin
|
Murphy, R.A.
|
|
|
20 |
S1 |
p. S36
|
artikel
|
| 11 |
EPS2.01 Drug-induced liver injury from antibiotics administered to adult cystic fibrosis patients: is it a problem? A single-centre retrospective study
|
Meredith, R.
|
|
|
20 |
S1 |
p. S32
|
artikel
|
| 12 |
EPS1.05 Evaluating impacts of the change from clinic to home spirometry on clinicians and adults with cystic fibrosis
|
Daniels, T.
|
|
|
20 |
S1 |
p. S30
|
artikel
|
| 13 |
EPS3.08 Evaluation of a fixed-step eradication regime in children with cystic fibrosis and detection of Pseudomonas aeruginosa
|
Grewendorf, S.F.
|
|
|
20 |
S1 |
p. S37
|
artikel
|
| 14 |
EPS1.08 Exercising online a “Beaming” good initiative
|
McCrea, G.
|
|
|
20 |
S1 |
p. S31
|
artikel
|
| 15 |
EPS2.09 F508del genotype is an independent risk factor for reduced bone mineral density in children with cystic fibrosis
|
Rodman Berlot, J.
|
|
|
20 |
S1 |
p. S34
|
artikel
|
| 16 |
EPS2.07 How did the COVID-19 lockdown influence the nutritional status and body composition of cystic fibrosis patients in Poland?
|
Mielus, M.
|
|
|
20 |
S1 |
p. S34
|
artikel
|
| 17 |
EPS1.07 Impact of COVID-19 on cystic fibrosis physiotherapy outpatient clinics
|
Scott, E.
|
|
|
20 |
S1 |
p. S31
|
artikel
|
| 18 |
EPS3.01 Is variation in Pseudomonas aeruginosa (Pa) surface-enhanced Raman spectroscopy (SERS) spectra related to phenotype?
|
Allen, D.
|
|
|
20 |
S1 |
p. S35
|
artikel
|
| 19 |
EPS2.03 Lumacaftor-ivacaftor therapy and its impact on glucose tolerance in children with cystic fibrosis
|
McGrath, K.
|
|
|
20 |
S1 |
p. S32
|
artikel
|
| 20 |
EPS3.05 N-chlorotaurine is a very promising antiseptic treatment option for multiresistant bacteria, fungi and for viruses including SARS-CoV-2
|
Schwarz, C.
|
|
|
20 |
S1 |
p. S36
|
artikel
|
| 21 |
EPS1.01 Physiotherapy practice of French cystic fibrosis children changed during lockdown due to COVID-19 pandemic
|
Mittaine, M.
|
|
|
20 |
S1 |
p. S29
|
artikel
|
| 22 |
EPS3.07 Predictors of eradication failure at first isolation of MRSA in children with cystic fibrosis
|
Ergenekon, P.
|
|
|
20 |
S1 |
p. S37
|
artikel
|
| 23 |
EPS2.10 Pregnancy and cystic fibrosis: patients’ experience from pre-conception to birth
|
Hagan, M.O.
|
|
|
20 |
S1 |
p. S35
|
artikel
|
| 24 |
EPS1.03 Recommended shielding against COVID-19 impacts physical activity levels and adherence to airway clearance therapy in patients with cystic fibrosis
|
Hatziagorou, E.
|
|
|
20 |
S1 |
p. S30
|
artikel
|
| 25 |
EPS1.02 The impact of COVID-19 on the prescribing practice of specialist cystic fibrosis physiotherapist non-medical prescribers in the UK
|
Brown, C.
|
|
|
20 |
S1 |
p. S29
|
artikel
|
| 26 |
EPS2.08 The model for determining risk groups for the development of vitamin D deficiency and prevention algorithm in children with cystic fibrosis using the multifactor dimensionality reduction method
|
Zhekaite, E.
|
|
|
20 |
S1 |
p. S34
|
artikel
|
| 27 |
EPS2.04 The role of Flash Glucose Monitoring System at annual review during the COVID-19 restrictions, within Cystic Fibrosis Diabetes Service at Blackpool Adult Cystic Fibrosis Centre, UK
|
Connolly, A.
|
|
|
20 |
S1 |
p. S32-S33
|
artikel
|
| 28 |
EPS3.03 Using airway organoids and Air Liquid Interface cultures to profile the spatial and temporal dynamics of Pseudomonas aeruginosa infections
|
Lolle, S.
|
|
|
20 |
S1 |
p. S35-S36
|
artikel
|
| 29 |
EPS3.02 Using rapid evaporative ionisation mass spectrometry (REIMS) for biomarker discovery and mechanistic studies of Pseudomonas aeruginosa stress responses
|
Bradley, R.
|
|
|
20 |
S1 |
p. S35
|
artikel
|
| 30 |
EPS2.06 What do people with cystic fibrosis eat? Diet quality, macronutrient and micronutrient intakes compared to recommended guidelines in adults with cystic fibrosis: a systematic literature review
|
Doyle, A.
|
|
|
20 |
S1 |
p. S33
|
artikel
|
| 31 |
P190 Adherence <50% to prescribed nebulisers in children with cystic fibrosis is associated with increased hospital admissions and lower FEV1 ZScore
|
Lock, K.J.
|
|
|
20 |
S1 |
p. S97
|
artikel
|
| 32 |
P059 A double-blind randomised multi-centre European study of linoleic acid supplementation for one year in patients with cystic fibrosis
|
Strandvik, B.
|
|
|
20 |
S1 |
p. S56
|
artikel
|
| 33 |
P171 Adult cystic fibrosis diabetes patient education and care needs: have your say - a patient survey
|
Kosbab-Jackson, K.
|
|
|
20 |
S1 |
p. S91
|
artikel
|
| 34 |
P242 Ageing with cystic fibrosis: how do older adults with cystic fibrosis adapt to change?
|
Stirk, S.
|
|
|
20 |
S1 |
p. S113
|
artikel
|
| 35 |
P036 Analysis of the dysfunction of cystic fibrosis macrophages
|
Rodriguez Gonzalez, C.
|
|
|
20 |
S1 |
p. S49
|
artikel
|
| 36 |
P021 An evaluation of the cystic fibrosis newborn screening service at Royal Manchester Children's Hospital - experience from a tertiary service provider in Northwest United Kingdom
|
Tharumakunarajah, R.
|
|
|
20 |
S1 |
p. S45
|
artikel
|
| 37 |
P038 An Italian centre experience with elexacaftor-tezacaftor-ivacaftor therapy in cystic fibrosis patients with advanced lung disease
|
Rosazza, C.
|
|
|
20 |
S1 |
p. S50
|
artikel
|
| 38 |
P007 A novel cystic fibrosis-causing mutation identified in a newborn of African origin
|
Cirilli, N.
|
|
|
20 |
S1 |
p. S40-S41
|
artikel
|
| 39 |
P208 Anxiety, depression and resilience during COVID-19 in Dutch patients with cystic fibrosis or primary ciliary dyskinesia and their caregivers
|
Verkleij, M.
|
|
|
20 |
S1 |
p. S102
|
artikel
|
| 40 |
P014 Are lower respiratory tract symptoms different in children with high immunoreactive trypsinogen levels?
|
Yilmaz, O.
|
|
|
20 |
S1 |
p. S42-S43
|
artikel
|
| 41 |
P045 Are people with cystic fibrosis reducing their medication since Kaftrio® initiation?
|
Dooney, M.K.
|
|
|
20 |
S1 |
p. S52
|
artikel
|
| 42 |
P075 Are there lessons to be learned from cystic fibrosis patient deaths and the timing of lung transplant referral?
|
Dave, K.
|
|
|
20 |
S1 |
p. S61-S62
|
artikel
|
| 43 |
P128 A reviewof inhaled corticosteroid prescribing in an adult cystic fibrosis population
|
Martin, N.
|
|
|
20 |
S1 |
p. S78
|
artikel
|
| 44 |
P230 A review of paediatric cystic fibrosis care during the COVID-19 pandemic
|
Powell, L.
|
|
|
20 |
S1 |
p. S109
|
artikel
|
| 45 |
P177 A review of vitamin levels in children with cystic fibrosis following the introduction of a multivitamin preparation
|
Gledhill, H.
|
|
|
20 |
S1 |
p. S93
|
artikel
|
| 46 |
P043 A snapshot of respiratory microbiology results pre- and postcommencing Kaftrio®
|
Jenkins, L.
|
|
|
20 |
S1 |
p. S51-S52
|
artikel
|
| 47 |
P110 A soft, flexible, wearable device for cough detection in paediatric cystic fibrosis patients
|
Tzavelis, A.
|
|
|
20 |
S1 |
p. S73
|
artikel
|
| 48 |
P126 Aspergillus fumigatus infection in patients with cystic fibrosis
|
Sciuca, S.
|
|
|
20 |
S1 |
p. S78
|
artikel
|
| 49 |
P216 Assessing patient satisfaction with the cystic fibrosis telehealth service
|
Yeo, S.
|
|
|
20 |
S1 |
p. S105
|
artikel
|
| 50 |
P199 Assessing the effectiveness of a six-month partially supervised outpatient exercise programme for adults with cystic fibrosis: a service evaluation
|
Banks, A.
|
|
|
20 |
S1 |
p. S99-S100
|
artikel
|
| 51 |
P226 A survey of family experience of cystic fibrosis care during the COVID-19 pandemic
|
Watkinson, J.
|
|
|
20 |
S1 |
p. S108
|
artikel
|
| 52 |
P193 Audit of cough swab sampling techniques in children with cystic fibrosis
|
Johnstone, Z.
|
|
|
20 |
S1 |
p. S98
|
artikel
|
| 53 |
P090 A UK survey on changes in managing people with cystic fibrosis during the COVID-19 pandemic
|
Hameed, M.S.
|
|
|
20 |
S1 |
p. S67
|
artikel
|
| 54 |
P219 Before and during the COVID-19 pandemic: a review of health of our paediatric cystic fibrosis patients
|
Powell, L.
|
|
|
20 |
S1 |
p. S106
|
artikel
|
| 55 |
P120 Bridging the gap – enhancing a multidisciplinary team Home IV service to reduce discrepancy in cystic fibrosis care
|
Kendall, V.
|
|
|
20 |
S1 |
p. S75-S76
|
artikel
|
| 56 |
P213 Can we attend anywhere? Evaluation of multidisciplinary team (MDT) remote consultations
|
Morrison, L.
|
|
|
20 |
S1 |
p. S104
|
artikel
|
| 57 |
P234 CFHealthHub a digital learning health system supporting virtual clinics and self-care across 60% of UK adult CF centres: a survey to understand benefits amongst the national CFDigiCare community
|
Cunningham, J.
|
|
|
20 |
S1 |
p. S110
|
artikel
|
| 58 |
P004 CFTR genotype in Russian patients with CBAVD syndrome
|
Marnat, E.
|
|
|
20 |
S1 |
p. S40
|
artikel
|
| 59 |
P020 CFTR mutation panel in detecting cystic fibrosis screen positive inconclusive diagnosis patients (CFSPIDs) in the Marche Region, Italy
|
Cirilli, N.
|
|
|
20 |
S1 |
p. S44
|
artikel
|
| 60 |
P224 Change in care during the COVID-19 pandemic: single-centre experience in a middle-income setting
|
Hatziagorou, E.
|
|
|
20 |
S1 |
p. S107
|
artikel
|
| 61 |
P098 Change in FEV1 after standardised care algorithm for cystic fibrosis patients: quality improvement project
|
Cenk, M.
|
|
|
20 |
S1 |
p. S69
|
artikel
|
| 62 |
P147 Changes in Pseudomonas aeruginosa phenotypes following the development of tobramycin resistance
|
McCleave, R.P.
|
|
|
20 |
S1 |
p. S84
|
artikel
|
| 63 |
P023 Characterisation of CFTR function in a patient with the F508del/ CFTRdup1–3 genotype
|
Cuyx, S.
|
|
|
20 |
S1 |
p. S45
|
artikel
|
| 64 |
P026 Characterisation of F508del-CFTR rescue by corrector MCG1516A
|
Lopes-Pacheco, M.
|
|
|
20 |
S1 |
p. S46
|
artikel
|
| 65 |
P032 Chemical optimisation of a PI3Kγ competing peptide for the therapy of cystic fibrosis
|
Della Sala, A.
|
|
|
20 |
S1 |
p. S48
|
artikel
|
| 66 |
P229 Children and young people with cystic fibrosis enhanced multidisciplinary pathways to address their educational needs during the evolving COVID-19 pandemic
|
Chandran, S.
|
|
|
20 |
S1 |
p. S108-S109
|
artikel
|
| 67 |
P130 Chronic inflammation biomarkers and lung function in cystic fibrosis patients
|
Dediu, M.
|
|
|
20 |
S1 |
p. S79
|
artikel
|
| 68 |
P245 Click and connect - a virtual group for young people with cystic fibrosis transitioning to high school
|
Phillips, B.
|
|
|
20 |
S1 |
p. S114
|
artikel
|
| 69 |
P116 Clinical characteristics of frequent and infrequent pulmonary exacerbations
|
Houston, C.J.
|
|
|
20 |
S1 |
p. S74
|
artikel
|
| 70 |
P077 Clinical factors affecting timing of referral for lung transplantation for people with cystic fibrosis: a national comparison of opinions between adult cystic fibrosis and transplant centres
|
Dave, K.
|
|
|
20 |
S1 |
p. S62-S63
|
artikel
|
| 71 |
P152 Clinical findings and long-term effect of methicillin-resistant Staphylococcus aureus isolation in patients with cystic fibrosis
|
Ozsezen, B.
|
|
|
20 |
S1 |
p. S85
|
artikel
|
| 72 |
P054 Clinical outcomes in people with cystic fibrosis treated with lumacaftor/ivacaftor in routine clinical practice in Sweden
|
Lindblad, A.
|
|
|
20 |
S1 |
p. S54-S55
|
artikel
|
| 73 |
P083 Clinical progression of SARS-CoV-2 infection in people with cystic fibrosis: a global observational study
|
McClenaghan, E.
|
|
|
20 |
S1 |
p. S65
|
artikel
|
| 74 |
P210 COACH project - screening for psychological comorbidity in adolescents with cystic fibrosis
|
Temming, S.
|
|
|
20 |
S1 |
p. S103
|
artikel
|
| 75 |
P063 Community involvement in shaping cystic fibrosis clinical trials
|
Allen, L.
|
|
|
20 |
S1 |
p. S57-S58
|
artikel
|
| 76 |
P040 Compassionate use triple therapy CFTR modulation (Kaftrio®) in severe disease. Single-centre, real-world clinical outcomes, safety and tolerability
|
Morrissy, D.
|
|
|
20 |
S1 |
p. S50-S51
|
artikel
|
| 77 |
P150 Competitive fitness experiments of cystic fibrosis isolates of Pseudomonas aeruginosa in human and murine precision-cut lung slices
|
Cramer, N.
|
|
|
20 |
S1 |
p. S85
|
artikel
|
| 78 |
P228 Concerns for people with cystic fibrosis when travelling pre-COVID-19
|
O'Doherty, M.
|
|
|
20 |
S1 |
p. S108
|
artikel
|
| 79 |
P215 Contrasting patient and paediatric cystic fibrosis team perception of telemedicine consultations
|
Kavaliunaite, E.
|
|
|
20 |
S1 |
p. S104-S105
|
artikel
|
| 80 |
P089 Coronavirus infection (COVID–19) in children with cystic fibrosis of the Russian Federation
|
Kondratyeva, E.
|
|
|
20 |
S1 |
p. S66-S67
|
artikel
|
| 81 |
P250 Correlation between care allowance levels and antibiotic treatment at the Stockholm Cystic Fibrosis Centre
|
Falk, E.
|
|
|
20 |
S1 |
p. S115
|
artikel
|
| 82 |
P137 COVID-19 in cystic fibrosis patients with and without lung transplantation: the Zurich cohort
|
Steinack, C.
|
|
|
20 |
S1 |
p. S81
|
artikel
|
| 83 |
P108 Cross-sectional and longitudinal comparison of N2 and SF6 multiple breath washout in children with cystic fibrosis aged 2–45 months
|
Mulvad Sandvik, R.
|
|
|
20 |
S1 |
p. S72
|
artikel
|
| 84 |
P111 CT-signs and the effectiveness of surgical treatment of sinonasal disease in children with cystic fibrosis
|
Gorinova, Y.
|
|
|
20 |
S1 |
p. S73
|
artikel
|
| 85 |
P170 Current status of cystic fibrosis-related diabetes in the Bulgarian cystic fibrosis population
|
Petrova, G.
|
|
|
20 |
S1 |
p. S90-S91
|
artikel
|
| 86 |
P057 Cystic fibrosis children not eligible for modulators therapy – data from a tertiary paediatric centre in Northwest United Kingdom
|
Mujtaba, G.
|
|
|
20 |
S1 |
p. S55-S56
|
artikel
|
| 87 |
P011 Cystic fibrosis – newborn screening (CF-NBS) start-up in Flanders (Belgium): report of first evaluation after two years
|
Proesmans, M.
|
|
|
20 |
S1 |
p. S41-S42
|
artikel
|
| 88 |
P069 Cystic fibrosis-related liver disease – a decade of experience
|
Mocic Pavic, A.
|
|
|
20 |
S1 |
p. S59-S60
|
artikel
|
| 89 |
P227 Cystic fibrosis social workers’ experience of working during COVID-19
|
Dowdall, F.
|
|
|
20 |
S1 |
p. S108
|
artikel
|
| 90 |
P217 Delivering quality improvement coaching in a virtual world: the use of digital technology to empower and engage CFDigiCare clinicians to undertake quality improvement activities nationally
|
Carolan, C.
|
|
|
20 |
S1 |
p. S105
|
artikel
|
| 91 |
P207 Depression and inflammation in people with cystic fibrosis: a pilot study
|
Ciciriello, F.
|
|
|
20 |
S1 |
p. S102
|
artikel
|
| 92 |
P160 Detection and management of nontuberculous mycobacteria in cystic fibrosis patients in a tertiary paediatric centre
|
Wayman, H.
|
|
|
20 |
S1 |
p. S88
|
artikel
|
| 93 |
P218 Detection of anxiety and depression through mental health screening questionnaires in cystic fibrosis patients and their families during the COVID-19 pandemic
|
Morales Tirado, A.
|
|
|
20 |
S1 |
p. S105-S106
|
artikel
|
| 94 |
P182 Developing a model for self-care support of diet and the gut in the routine care of children with cystic fibrosis: a qualitative study
|
Cave, L.
|
|
|
20 |
S1 |
p. S94
|
artikel
|
| 95 |
P254 Development of a primary palliative care model that includes a novel approach to address the needs of caregivers of adults with cystic fibrosis - improving life with cystic fibrosis: a primary palliative care partnership
|
Georgiopoulos, A.M.
|
|
|
20 |
S1 |
p. S116-S117
|
artikel
|
| 96 |
P017 Different ethnical distribution of the incidence of cystic fibrosis in Republic of North Macedonia
|
Anastasovska, V.
|
|
|
20 |
S1 |
p. S43
|
artikel
|
| 97 |
P148 Different treatment regimens in first isolation of Pseudomonas aeruginosa
|
Yilmaz Yegit, C.
|
|
|
20 |
S1 |
p. S84
|
artikel
|
| 98 |
P257 Directions of psychological and pedagogical support of children with cystic fibrosis
|
Sviridova, T.
|
|
|
20 |
S1 |
p. S117
|
artikel
|
| 99 |
P050 Drug desensitisation for lumacaftor/ivacaftor - step-by-step to drug tolerance
|
Westhoff, J.
|
|
|
20 |
S1 |
p. S53
|
artikel
|
| 100 |
P197 Dysglycaemia and changes in aerobic function in cystic fibrosis
|
Tomlinson, O.
|
|
|
20 |
S1 |
p. S99
|
artikel
|
| 101 |
P115 Effectiveness of different eradication treatment protocols for the first Pseudomonas aeruginosa isolation in paediatric cystic fibrosis patients
|
Sunman, B.
|
|
|
20 |
S1 |
p. S74
|
artikel
|
| 102 |
P095 Effect of age and genotype on lung function in children with cystic fibrosis
|
Shadrina, V.
|
|
|
20 |
S1 |
p. S68
|
artikel
|
| 103 |
P041 Effect of the triple combination of CFTR correctors and potentiator on lung function, BMI and the Brasfield score in adolescents with cystic fibrosis
|
Praprotnik, M.
|
|
|
20 |
S1 |
p. S51
|
artikel
|
| 104 |
P163 Effects of the SARS-CoV-2 pandemic on attendance at the cystic fibrosis centre and the definition of the microbiological status of cystic fibrosis patients in Tuscany
|
Dolce, D.
|
|
|
20 |
S1 |
p. S88-S89
|
artikel
|
| 105 |
P037 Elexacaftor/tezacaftor/ivacaftor improve lung disease in patients with advanced cystic fibrosis homozygous for the F508del mutation
|
Carnovale, V.
|
|
|
20 |
S1 |
p. S49-S50
|
artikel
|
| 106 |
P092 Embedding an electronic patient record into a developing UK service and impact during the COVID-19 pandemic - Blackpool Adult Cystic Fibrosis Service (BACFS)
|
Pickering, N.
|
|
|
20 |
S1 |
p. S67
|
artikel
|
| 107 |
P238 EMBRACEing Medicines Optimisation: working collaboratively to identify barriers and share solutions in the medication pathway across 12 sites within the CFHealthHub
|
Carolan, C.
|
|
|
20 |
S1 |
p. S112
|
artikel
|
| 108 |
P070 Epidemiology of nontuberculous mycobacteria in a single adult cystic fibrosis centre
|
Kumar, A.
|
|
|
20 |
S1 |
p. S60
|
artikel
|
| 109 |
P068 Estimating the long-term effects of insulin on outcomes in cystic fibrosis-related diabetes: a target trial approach
|
Granger, E.
|
|
|
20 |
S1 |
p. S59
|
artikel
|
| 110 |
P139 Evaluating the impact of a telemedicine service during the COVID-19 pandemic in people with cystic fibrosis
|
Bull, A.
|
|
|
20 |
S1 |
p. S81
|
artikel
|
| 111 |
P099 Evaluation by plethismography of cystic fibrosis and non-cystic fibrosis patients
|
Balanetchi, L.
|
|
|
20 |
S1 |
p. S69
|
artikel
|
| 112 |
P252 Evaluation of a dashboard-style 1-page colour cystic fibrosis annual review summary as a novel feedback method to improve communication with families and aid multidisciplinary teams
|
Coates, A.J.
|
|
|
20 |
S1 |
p. S116
|
artikel
|
| 113 |
P022 Evaluation of hearing and vestibular system in patients with cystic fibrosis
|
Ozsezen, B.
|
|
|
20 |
S1 |
p. S45
|
artikel
|
| 114 |
P013 Evaluation of improvements of the cystic fibrosis newborn screening protocol in the Netherlands
|
Bouva, M.
|
|
|
20 |
S1 |
p. S42
|
artikel
|
| 115 |
P196 Evaluation of the efficiency of Frequencer™and Vest airways clearance devices in adult cystic fibrotic patients
|
Borka, P.
|
|
|
20 |
S1 |
p. S99
|
artikel
|
| 116 |
P015 Evaluation of the specificity and sensitivity of the cut-off values of immunoreactive trypsinogen in the cystic fibrosis newborn screening program
|
Ramasli Gursoy, T.
|
|
|
20 |
S1 |
p. S43
|
artikel
|
| 117 |
P149 Evolution of levofloxacin resistance and phenotypic characterisation of Pseudomonas aeruginosa clinical isolates from people with cystic fibrosis
|
Sloan, C.M.
|
|
|
20 |
S1 |
p. S84-S85
|
artikel
|
| 118 |
P154 Exophiala dermatitidis can undergo patient-patient transmission in cystic fibrosis patients
|
Ayling-Smith, J.
|
|
|
20 |
S1 |
p. S86
|
artikel
|
| 119 |
P153 Exophiala dermatitidis infection in cystic fibrosis patients accelerates lung function decline: a retrospective single-centre reviewof historical lung function
|
Ayling-Smith, J.
|
|
|
20 |
S1 |
p. S86
|
artikel
|
| 120 |
P220 Experiences of virtual cystic fibrosis clinics during the COVID-19 pandemic at one UK adult cystic fibrosis centre
|
Warnock, L.
|
|
|
20 |
S1 |
p. S106
|
artikel
|
| 121 |
P094 Facilitating cystic fibrosis research during the COVID-19 pandemic
|
Burnett, S.
|
|
|
20 |
S1 |
p. S68
|
artikel
|
| 122 |
P123 Features of the immune response to Mycobacterium abscessus complex (MABSC) and the influence of BCG vaccination
|
Mauch, R.
|
|
|
20 |
S1 |
p. S76
|
artikel
|
| 123 |
P203 Fertile ground: pregnancies in a post-Kaftrio® pandemic era
|
Lillis, A.
|
|
|
20 |
S1 |
p. S101
|
artikel
|
| 124 |
P029 First report: Kaftrio® vs. Symkevi® in intestinal organoids
|
Furstova, E.
|
|
|
20 |
S1 |
p. S47
|
artikel
|
| 125 |
P018 Follow-up of children with Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID) in Switzerland
|
Imahorn, O.
|
|
|
20 |
S1 |
p. S44
|
artikel
|
| 126 |
P180 Food access challenges and social needs for people with cystic fibrosis
|
Clemm, C.
|
|
|
20 |
S1 |
p. S93
|
artikel
|
| 127 |
P158 Fungal airway colonisation in cystic fibrosis patients in the Institute for Respiratory Diseases in Children - Skopje, Republic of North Macedonia
|
Arnaudova Danevska, I.
|
|
|
20 |
S1 |
p. S87
|
artikel
|
| 128 |
P002 Genetic characteristics of the cystic fibrosis Polish patients registered in the public Matio Polish Cystic Fibrosis Foundation
|
Surma, K.
|
|
|
20 |
S1 |
p. S39
|
artikel
|
| 129 |
P184 Going green: patient awareness of inhaler indication, usage and environmental impact
|
Snow, K.
|
|
|
20 |
S1 |
p. S95
|
artikel
|
| 130 |
P179 Has COVID-19 affected the management of vitamin D status amongst people with cystic fibrosis?
|
Ochota, A.
|
|
|
20 |
S1 |
p. S93
|
artikel
|
| 131 |
P141 Has the COVID-19 pandemic affected medication adherence to inhaled nebulised therapy for patients at a large adult cystic fibrosis centre?
|
Iqbal, N.
|
|
|
20 |
S1 |
p. S82
|
artikel
|
| 132 |
P185 Health literacy in children with cystic fibrosis
|
Millar, C.
|
|
|
20 |
S1 |
p. S95
|
artikel
|
| 133 |
P064 How does early weight gain explain the effect of childhood socioeconomic conditions on lung function for children with cystic fibrosis? A UK Registry-based study
|
Schlüter, D.
|
|
|
20 |
S1 |
p. S58
|
artikel
|
| 134 |
P155 Identification of an evolutionary split in Bukholderia multivorans using phylogenomics: does it have any impacts on the ability to cause cystic fibrosis lung infection?
|
Parfitt, K.
|
|
|
20 |
S1 |
p. S86
|
artikel
|
| 135 |
P027 Identification of corrector combinations to increase the rescue of F508del-CFTR traffic and function
|
Castela Ferreira, F.
|
|
|
20 |
S1 |
p. S46-S47
|
artikel
|
| 136 |
P028 Identification of novel F508del-CFTR correctors among triazole derivative compounds
|
Bacalhau, M.
|
|
|
20 |
S1 |
p. S47
|
artikel
|
| 137 |
P008 Identification of two novel mutations (c.3639dup and ex16-17a dup) in the CFTR gene in Polish patient with cystic fibrosis
|
Wardak, S.
|
|
|
20 |
S1 |
p. S41
|
artikel
|
| 138 |
P088 Impact of COVID-19 and cocooning on employment of people with cystic fibrosis
|
Bhatnagar, R.
|
|
|
20 |
S1 |
p. S66
|
artikel
|
| 139 |
P085 Impact of COVID-19 on hospital services and specialist care of adults with cystic fibrosis
|
Bhatnagar, R.
|
|
|
20 |
S1 |
p. S65
|
artikel
|
| 140 |
P087 Impact of COVID-19 on mental health of children with cystic fibrosis and their parents
|
Bhatnagar, R.
|
|
|
20 |
S1 |
p. S66
|
artikel
|
| 141 |
P125 Impact of infection with Achromobacter spp. on clinical outcome in paediatric patients with cystic fibrosis
|
Sunman, B.
|
|
|
20 |
S1 |
p. S77
|
artikel
|
| 142 |
P133 Impact of specialised pro-resolving lipid mediators on cystic fibrosis airway epithelial cell functions
|
Briottet, M.
|
|
|
20 |
S1 |
p. S79-S80
|
artikel
|
| 143 |
P047 Impact of tezacaftor/ivacaftor/elexecaftor on outcome in patient with I336K–mutation and a minimal function mutation (R553X)
|
Sutharsan, S.
|
|
|
20 |
S1 |
p. S53
|
artikel
|
| 144 |
P062 Impact of the SARS-CoV-2 pandemic on clinical trials in the ECFS-CTN during 2020
|
Van Koningsbruggen-Rietschel, S.
|
|
|
20 |
S1 |
p. S57
|
artikel
|
| 145 |
P189 Impact of triple CFTR modulation therapy on non-invasive ventilation use in adults with cystic fibrosis
|
Wadsworth, L.E.
|
|
|
20 |
S1 |
p. S96-S97
|
artikel
|
| 146 |
P194 Implementation of a cystic fibrosis-specific virtual pulmonary rehab program
|
Fordyce, C.M.
|
|
|
20 |
S1 |
p. S98
|
artikel
|
| 147 |
P124 Implementing an anti-emetic protocol improves morbidity associated with intravenous therapy for Mycobacterium abscessus in children
|
Menon, A.
|
|
|
20 |
S1 |
p. S77
|
artikel
|
| 148 |
P151 Improved isolation yields for bacteriophage active against Staphylococcus aureus
|
Iszatt, J.
|
|
|
20 |
S1 |
p. S85
|
artikel
|
| 149 |
P247 Improved quality of care increases lung function and growth parameters in children with cystic fibrosis
|
Beaufils, F.
|
|
|
20 |
S1 |
p. S114-S115
|
artikel
|
| 150 |
P165 Improvement in antibiotic usage and ppFEV1 with compassionate use of elexacaftor, tezacaftor and ivacaftor (ETI) for patients with cystic fibrosis
|
Baker, O.
|
|
|
20 |
S1 |
p. S89
|
artikel
|
| 151 |
P119 Improving Home IV outcomes
|
Ryan, C.
|
|
|
20 |
S1 |
p. S75
|
artikel
|
| 152 |
P240 Improving the accuracy of nebuliser prescriptions (and update where necessary) during the medication reconciliation process on CFHealthHub (within 24-hours)
|
White, R.
|
|
|
20 |
S1 |
p. S112-S113
|
artikel
|
| 153 |
P019 Inconclusive Cystic Fibrosis Positive Neonatal Screening (CFSPID): clinical outcomes
|
Gartner, S.
|
|
|
20 |
S1 |
p. S44
|
artikel
|
| 154 |
P055 Increased pulmonary interstitial fluid at CFTR modulator therapy start
|
Krivec, U.
|
|
|
20 |
S1 |
p. S55
|
artikel
|
| 155 |
P129 Induced sputum as a minimally invasive sample to investigate airway inflammation in the early course of cystic fibrosis
|
Giacalone, V.
|
|
|
20 |
S1 |
p. S78-S79
|
artikel
|
| 156 |
P073 Influence of assessment tool and publication type on the reported prevalence of depression and anxiety in adults with cystic fibrosis: a meta-analysis
|
Lord, L.
|
|
|
20 |
S1 |
p. S61
|
artikel
|
| 157 |
P258 Integrating a diabetes service within the Adult Cystic Fibrosis Service at Blackpool Victoria Hospital, UK
|
Knowles, J.
|
|
|
20 |
S1 |
p. S118
|
artikel
|
| 158 |
P113 Integration of Qi Gong sessions into a respiratory rehabilitation program: the experience of the CF Centre in Roscoff (France)
|
Ramel, S.
|
|
|
20 |
S1 |
p. S73-S74
|
artikel
|
| 159 |
P056 Intestinal current measurement (ICM) in cystic fibrosis paediatric patients - a pilot study
|
Postek, M.
|
|
|
20 |
S1 |
p. S55
|
artikel
|
| 160 |
P146 Intra-patient evolution of a pulmonary strain of Pseudomonas aeruginosa, from primocolonisation to lung transplant
|
Gaillot, S.
|
|
|
20 |
S1 |
p. S83
|
artikel
|
| 161 |
P173 Investigation of cyproheptadine as an appetite stimulator in 6 children with cystic fibrosis with a suboptimal nutritional status
|
Van Meerbeeck, S.
|
|
|
20 |
S1 |
p. S91
|
artikel
|
| 162 |
P035 iPSC-derived macrophages from cystic fibrosis patients as a cell source to establish in vitro infection models and a drug screening platform
|
Rodríguez-González, C.
|
|
|
20 |
S1 |
p. S49
|
artikel
|
| 163 |
P209 Key priorities in mental health research: results of a community and provider survey across the US
|
Smith, B.A.
|
|
|
20 |
S1 |
p. S103
|
artikel
|
| 164 |
P103 Longitudinal SF6 multiple breath washout testing in children aged 0–4 years with cystic fibrosis
|
Mulvad Sandvik, R.
|
|
|
20 |
S1 |
p. S70
|
artikel
|
| 165 |
P096 Long-term follow-up of adolescent and adult patients with cystic fibrosis: a single centre's experience
|
Yilmaz, A.I.
|
|
|
20 |
S1 |
p. S68
|
artikel
|
| 166 |
P142 Lung and gut microbiota signatures in cystic fibrosis mice challenged with Pseudomonas aeruginosa
|
Bevivino, A.
|
|
|
20 |
S1 |
p. S82
|
artikel
|
| 167 |
P107 Lung clearance index in Bulgarian children with cystic fibrosis
|
Gospodinova, B.
|
|
|
20 |
S1 |
p. S71-S72
|
artikel
|
| 168 |
P105 Lung clearance index in monitoring response to antibiotic therapy in children with cystic fibrosis
|
Walicka-Serzysko, K.
|
|
|
20 |
S1 |
p. S71
|
artikel
|
| 169 |
P066 Lung function and pulmonary exacerbations among individuals with cystic fibrosis living near composting facilities in the United Kingdom
|
Saleem Khan, M.
|
|
|
20 |
S1 |
p. S58-S59
|
artikel
|
| 170 |
P118 Lung ultrasound in cystic fibrosis exacerbations
|
Ciuca, I.M.
|
|
|
20 |
S1 |
p. S75
|
artikel
|
| 171 |
P052 Managing the rollout of the cystic fibrosis modulator therapy Kaftrio® at a large UK adult centre
|
Takawira, C.
|
|
|
20 |
S1 |
p. S54
|
artikel
|
| 172 |
P187 Measuring the effect of airway clearance in adults with cystic fibrosis – a systematic review
|
Stanford, G.E.
|
|
|
20 |
S1 |
p. S96
|
artikel
|
| 173 |
P067 Mechanisms for the effect of CFRD on mortality: a causal mediation analysis using UK cystic fibrosis Registry data
|
Tanner, K.T.
|
|
|
20 |
S1 |
p. S59
|
artikel
|
| 174 |
P249 Men's health in cystic fibrosis in the modern era: a qualitative study
|
Kazmerski, T.M.
|
|
|
20 |
S1 |
p. S115
|
artikel
|
| 175 |
P046 Menstrual abnormalities linked to Kaftrio®
|
Dooney, M.K.
|
|
|
20 |
S1 |
p. S52-S53
|
artikel
|
| 176 |
P030 Metabolomic impact of the restoration of CFTR activity in the respiratory epithelium
|
Bardin, E.
|
|
|
20 |
S1 |
p. S47-S48
|
artikel
|
| 177 |
P143 Microevolution of Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis
|
Avetisyan, L.
|
|
|
20 |
S1 |
p. S82-S83
|
artikel
|
| 178 |
P241 “Middle-aged” cystic fibrosis patients’ experiences of living with cystic fibrosis: a qualitative study
|
Backström-Eriksson, L.
|
|
|
20 |
S1 |
p. S113
|
artikel
|
| 179 |
P005 “Mild” variants of the CFTR gene in Russian patients without clinical manifestations
|
Melyanovskaya, Y.
|
|
|
20 |
S1 |
p. S40
|
artikel
|
| 180 |
P157 Monitoring the distribution and genotypic diversity of Burkholderiales bacteria in Russian cystic fibrosis patients in the year of the COVID-19 pandemic
|
Voronina, O.
|
|
|
20 |
S1 |
p. S87
|
artikel
|
| 181 |
P244 Moving from paediatric to adult care: resources to support transition
|
Davis-Bollard, H.
|
|
|
20 |
S1 |
p. S114
|
artikel
|
| 182 |
P104 Multiple-breath nitrogen washout test and structural lung damage in adult patients with cystic fibrosis
|
Cherniak, A.
|
|
|
20 |
S1 |
p. S71
|
artikel
|
| 183 |
P144 Mutations in chromosomal genes responsible for T3SS of Pseudomonas aeruginosa strains isolated from cystsic fibrosis patient lungs
|
Chernukha, M.
|
|
|
20 |
S1 |
p. S83
|
artikel
|
| 184 |
P156 Mycobacterium abscessus treatment in adult patients with cystic fibrosis: case series and review
|
Alameeri, A.
|
|
|
20 |
S1 |
p. S86-S87
|
artikel
|
| 185 |
P114 Neutrophil effector responses to cystic fibrosis clinical isolates of Pseudomonas aeruginosa
|
Fantone, K.
|
|
|
20 |
S1 |
p. S74
|
artikel
|
| 186 |
P010 Newborn screening for cystic fibrosis improves nutritional outcome: monocentric data of the first 4 years in Germany
|
Schütz, K.
|
|
|
20 |
S1 |
p. S41
|
artikel
|
| 187 |
P065 Newborn screening-related clinical pathomorphosis of cystic fibrosis in children living in KHMAO-Ugra (Russia)
|
Donnikov, M.
|
|
|
20 |
S1 |
p. S58
|
artikel
|
| 188 |
P188 Non-invasive ventilation use and management of adult cystic fibrosis patients at end of life
|
Wadsworth, L.E.
|
|
|
20 |
S1 |
p. S96
|
artikel
|
| 189 |
P034 Novel insights into the therapeutic potential of antisense oligonucleotides as splicing modulators in respiratory and intestinal patient-derived model systems
|
Stanleigh, N.
|
|
|
20 |
S1 |
p. S49
|
artikel
|
| 190 |
P175 Nutritional status, lung function and adequacy of micronutrient supplementation in children with cystic fibrosis
|
Niseteo, T.
|
|
|
20 |
S1 |
p. S92
|
artikel
|
| 191 |
P181 Nutrition support at an adult cystic fibrosis centre
|
Mitchell-Whyte, M.
|
|
|
20 |
S1 |
p. S94
|
artikel
|
| 192 |
P048 Olfactory dysfunction: impact of highly effective modulator therapy
|
Beswick, D.
|
|
|
20 |
S1 |
p. S53
|
artikel
|
| 193 |
P255 Parenthood experience of cystic fibrosis patients and their spouses
|
Jacob, A.
|
|
|
20 |
S1 |
p. S117
|
artikel
|
| 194 |
P225 Parents’ feedback on virtual paediatric cystic fibrosis clinics during COVID-19 pandemic
|
Powell, M.
|
|
|
20 |
S1 |
p. S107-S108
|
artikel
|
| 195 |
P231 Patient experience of accessing a virtual cystic fibrosis service during the 2020 SARS-CoV-2 pandemic in Blackpool, North West of England
|
Sanderson-Thomas, A.
|
|
|
20 |
S1 |
p. S109
|
artikel
|
| 196 |
P172 Patient experience of Manchester Virtual Cystic Fibrosis-Related Diabetes Clinic during the COVID-19 pandemic
|
Brennan, A.
|
|
|
20 |
S1 |
p. S91
|
artikel
|
| 197 |
P206 Patient feedback following the introduction of a dedicated ‘Symkevi® Initiation Clinic’ prior to starting modulator therapy
|
Haigh, L.
|
|
|
20 |
S1 |
p. S102
|
artikel
|
| 198 |
P205 Patient-reported outcome measures in the current context of new generation modulator therapies in cystic fibrosis
|
Hayes, K.
|
|
|
20 |
S1 |
p. S101-S102
|
artikel
|
| 199 |
P248 Patient Science: a new citizen science approach for health and medical research involving people affected by cystic fibrosis
|
Gardecki, J.
|
|
|
20 |
S1 |
p. S115
|
artikel
|
| 200 |
P060 Phage therapy for chronic Pseudomonas aeruginosa infections in cystic fibrosis patients
|
Kahan-Hanum, M.
|
|
|
20 |
S1 |
p. S56
|
artikel
|
| 201 |
P198 Physical activity is associated with aerobic capacity and lung function in adults with cystic fibrosis
|
Curran, M.
|
|
|
20 |
S1 |
p. S99
|
artikel
|
| 202 |
P024 Pili annulati: is it a new finding in cystic fibrosis?
|
Daye, M.
|
|
|
20 |
S1 |
p. S46
|
artikel
|
| 203 |
P162 Pneumococcal and influenza vaccination coverage level: data from a cystic fibrosis centre
|
Hatziagorou, E.
|
|
|
20 |
S1 |
p. S88
|
artikel
|
| 204 |
P106 Positioning may not affect lung clearance index
|
Baker, T.
|
|
|
20 |
S1 |
p. S71
|
artikel
|
| 205 |
P166 Prevalence of cystic fibrosis-associated liver disease in Albanian cystic fibrosis patients
|
Kasmi, I.
|
|
|
20 |
S1 |
p. S89-S90
|
artikel
|
| 206 |
P167 Prevalence of liver disease in cystic fibrosis patients in the Institute for Respiratory Diseases in Children - Skopje, Republic of North Macedonia
|
Arnaudova Danevska, I.
|
|
|
20 |
S1 |
p. S90
|
artikel
|
| 207 |
P101 Provision of home spirometry in a physiologist-led service: experiences from a large adult cystic fibrosis centre
|
Hawkes, S.
|
|
|
20 |
S1 |
p. S70
|
artikel
|
| 208 |
P072 Psychometric validation of the Cystic Fibrosis Impact Questionnaire: a patient-reported outcome instrument assessing the life impacts of cystic fibrosis
|
Serrano, D.
|
|
|
20 |
S1 |
p. S60
|
artikel
|
| 209 |
P239 Pulmonary medication adherence among children and adults with cystic fibrosis
|
Hatziagorou, E.
|
|
|
20 |
S1 |
p. S112
|
artikel
|
| 210 |
P127 Pulsed intravenous methylprednisolone for allergic bronchopulmonary aspergillosis in cystic fibrosis
|
Thornton, T.
|
|
|
20 |
S1 |
p. S78
|
artikel
|
| 211 |
P100 Quality of home spirometry performance amongst adults with cystic fibrosis
|
Bell, J.
|
|
|
20 |
S1 |
p. S69
|
artikel
|
| 212 |
P221 Quality of life in adult and children with cystic fibrosis during the COVID-19 pandemic in Croatia
|
Odobasic Palkovic, T.
|
|
|
20 |
S1 |
p. S106
|
artikel
|
| 213 |
P236 Quantifying the ‘under-served’ or ‘hard to reach but reachable’ people with cystic fibrosis in two UK adult cystic fibrosis centres
|
Dawson, S.
|
|
|
20 |
S1 |
p. S111
|
artikel
|
| 214 |
P138 Rapid implementation of virtual clinics during the COVID-19 pandemic
|
Nazareth, D.
|
|
|
20 |
S1 |
p. S81
|
artikel
|
| 215 |
P053 Real-life clinical effects of therapy with lumacaftor and ivacaftor in patients with cystic fibrosis
|
Comello, I.
|
|
|
20 |
S1 |
p. S54
|
artikel
|
| 216 |
P071 Real-world pregnancy data and outcomes in an era post-CFTR modulation therapies: an Irish centre's perspective
|
Ratjen, A.
|
|
|
20 |
S1 |
p. S60
|
artikel
|
| 217 |
P042 RECOVER - the Real World Clinical Outcomes with Novel Modulator therapy combinations in people with cystic fibrosis
|
McNally, P.
|
|
|
20 |
S1 |
p. S51
|
artikel
|
| 218 |
P132 Reduced systemic immune responses in cystic fibrosis patients
|
Lausen, M.
|
|
|
20 |
S1 |
p. S79
|
artikel
|
| 219 |
P109 Regional assessment of lung function using non-contrast MRI in people with cystic fibrosis
|
Brooke, J.P.
|
|
|
20 |
S1 |
p. S72
|
artikel
|
| 220 |
P091 Regularity of check-ups at the cystic fibrosis centre in the time of COVID-19 pandemic
|
Todorić, I.
|
|
|
20 |
S1 |
p. S67
|
artikel
|
| 221 |
P159 Relationship between clinical and environmental strains of emerging opportunistic pathogens in cystic fibrosis and diversity in the home environment
|
Menetrey, Q.
|
|
|
20 |
S1 |
p. S87-S88
|
artikel
|
| 222 |
P136 Relationship between cystic fibrosis disease severity and susceptibility to COVID-19 infection
|
Atalay, M.
|
|
|
20 |
S1 |
p. S80-S81
|
artikel
|
| 223 |
P051 Rollout of Kaftrio® to adult cystic fibrosis patients at the Royal Brompton Hospital during a global pandemic
|
Bowman, E.
|
|
|
20 |
S1 |
p. S53-S54
|
artikel
|
| 224 |
P134 SARS-CoV-2 infection in cystic fibrosis during the first pandemic wave in Italy: a multi-centre prospective study with a control group
|
Colombo, C.
|
|
|
20 |
S1 |
p. S80
|
artikel
|
| 225 |
P135 SARS-COV-2 infection in patients with cystic fibrosis
|
Balanetchi, L.
|
|
|
20 |
S1 |
p. S80
|
artikel
|
| 226 |
P074 Setting up a framework for the collection of patient-reported outcomes in the real world: trials and tribulations
|
Lammertyn, E.
|
|
|
20 |
S1 |
p. S61
|
artikel
|
| 227 |
P253 Share the sunshine to improve staff well-being
|
Simmons, S.
|
|
|
20 |
S1 |
p. S116
|
artikel
|
| 228 |
P112 Sleep disorders and exercise capacity in adult patients with cystic fibrosis in the Republic of North Macedonia
|
Jakovska Maretti, T.
|
|
|
20 |
S1 |
p. S73
|
artikel
|
| 229 |
P222 Supporting children with cystic fibrosis: building social networks through the pandemic
|
Mindel, E. Lee
|
|
|
20 |
S1 |
p. S107
|
artikel
|
| 230 |
P200 Supporting exercise services in cystic fibrosis: five years of the UKCystic Fibrosis & Exercise Network
|
Tomlinson, O.
|
|
|
20 |
S1 |
p. S100
|
artikel
|
| 231 |
P025 Systems biology modelling of CFTR maturation to predict possible active compound combinations
|
Vinhoven, L.
|
|
|
20 |
S1 |
p. S46
|
artikel
|
| 232 |
P001 TCRß repertoire in monozygotic cystic fibrosis twins
|
Tümmler, B.
|
|
|
20 |
S1 |
p. S39
|
artikel
|
| 233 |
P140 TeCC (TeleMedicine, Cystic Fibrosis, Corona-Virus) study in a previous telemedicine-naive centre: clinical challenges, outcomes, and user experience in the first six months of a global pandemic
|
Morrissy, D.
|
|
|
20 |
S1 |
p. S81-S82
|
artikel
|
| 234 |
P080 Temporal disparity between hospital episode statistics and the UK cystic fibrosis Registry
|
Murrin, O.
|
|
|
20 |
S1 |
p. S64
|
artikel
|
| 235 |
P174 The association between body composition and respiratory outcomes for patients with cystic fibrosis
|
Sheibani, L.
|
|
|
20 |
S1 |
p. S92
|
artikel
|
| 236 |
P176 The benefits of changing to a cystic fibrosis-specific combined fatsoluble vitamin supplement: vitamin status, tablet burden and adherence
|
Marsden, K.
|
|
|
20 |
S1 |
p. S92
|
artikel
|
| 237 |
P078 The burden of cystic fibrosis beyond medical costs in Switzerland
|
Tzogiou, C.
|
|
|
20 |
S1 |
p. S63
|
artikel
|
| 238 |
P039 The clinical impact of triple CFTR modulator therapy in a cohort of people with cystic fibrosis and severe lung disease
|
Fanthorpe, O.
|
|
|
20 |
S1 |
p. S50
|
artikel
|
| 239 |
P006 The complex allele c.[1399C>T;1521_1523delCTT] (L467F;F508del) of the CFTR gene in Russian cystic fibrosis patients
|
Petrova, N.
|
|
|
20 |
S1 |
p. S40
|
artikel
|
| 240 |
P201 The effectiveness of exercise interventions to increase physical activity in cystic fibrosis: a systematic review
|
Curran, M.
|
|
|
20 |
S1 |
p. S100
|
artikel
|
| 241 |
P058 The effect of hypertonic saline treatment in pre-schoolers with cystic fibrosis on lung structure as measured by chest computed tomography. SHIP-CT study
|
Tiddens, H.A.
|
|
|
20 |
S1 |
p. S56
|
artikel
|
| 242 |
P121 The effect of training about nebuliser cleaning and disinfection on the knowledge levels and practises of the caregivers of patients with cystic fibrosis
|
Cenk, M.
|
|
|
20 |
S1 |
p. S76
|
artikel
|
| 243 |
P202 The evaluation of sinonasal and health symptoms in children with cystic fibrosis on Orkambi® or Symkevi® using the SNOT-22
|
Murray, G.
|
|
|
20 |
S1 |
p. S100-S101
|
artikel
|
| 244 |
P251 The experience of adults with cystic fibrosis engaging in a complex health management regime: a meta-ethnography
|
Stirk, S.
|
|
|
20 |
S1 |
p. S116
|
artikel
|
| 245 |
P086 The impact of COVID-19 in people with cystic fibrosis – a single-centre experience
|
Aldous, G.
|
|
|
20 |
S1 |
p. S66
|
artikel
|
| 246 |
P232 The impact of COVID-19 on the relationships between parents of young people diagnosed with cystic fibrosis and the cystic fibrosis multidisciplinary team
|
Jones, S.
|
|
|
20 |
S1 |
p. S109
|
artikel
|
| 247 |
P044 The impact of the highly effective modulator therapy, Kaftrio®, on glucose regulation in adolescents with cystic fibrosis
|
Walsh, A.
|
|
|
20 |
S1 |
p. S52
|
artikel
|
| 248 |
P084 The impact of the SARS-CoV-2 pandemic on people living with cystic fibrosis in Ireland: real-world data from the Irish cystic fibrosis registry
|
Rees, H.
|
|
|
20 |
S1 |
p. S65
|
artikel
|
| 249 |
P161 The influence of chronic lung infections on the development of bronchiectasis in patients with cystic fibrosis
|
Balanetchi, L.
|
|
|
20 |
S1 |
p. S88
|
artikel
|
| 250 |
P192 The introduction of a quality improvement focus group in a large UK adult cystic fibrosis centre
|
Choyce, J.
|
|
|
20 |
S1 |
p. S97-S98
|
artikel
|
| 251 |
P009 The investigation of the effect of electrolyte disorder on sweat test in newborns with positive cystic fibrosis screening test
|
Erdinc, E.
|
|
|
20 |
S1 |
p. S41
|
artikel
|
| 252 |
P031 The last 10%: small molecule screening for correctors of rare CFTRprocessing mutations
|
Ensinck, M.
|
|
|
20 |
S1 |
p. S48
|
artikel
|
| 253 |
P082 The National Cystic Fibrosis Patient Registry of the Russian Federation – 9 years of experience (2011–2019)
|
Kashirskaya, N.
|
|
|
20 |
S1 |
p. S64
|
artikel
|
| 254 |
P003 The possibilities of target of cystic fibrosis in the Republic of Moldova taking into account the analysis of CFTR mutations range
|
Barbova, N.
|
|
|
20 |
S1 |
p. S39
|
artikel
|
| 255 |
P243 The psychological impact of the late diagnosis of atypical cystic fibrosis patients
|
Petrova, G.
|
|
|
20 |
S1 |
p. S113-S114
|
artikel
|
| 256 |
P033 Therapeutic approach by translational suppression of non-sens mutation in CFTR gene
|
Karri, S.
|
|
|
20 |
S1 |
p. S48
|
artikel
|
| 257 |
P117 The respiratory pathogen colonisation and lung function in cystic fibrosis patients
|
Sciuca, S.
|
|
|
20 |
S1 |
p. S75
|
artikel
|
| 258 |
P237 The role of beliefs in predicting adherence to nebulised medications in adolescents with cystic fibrosis
|
Stirzaker, B.M.
|
|
|
20 |
S1 |
p. S111
|
artikel
|
| 259 |
P016 The role of clinical and laboratory findings in the diagnosis of cystic fibrosis in children with positive newborn screening
|
Asfuroglu, P.
|
|
|
20 |
S1 |
p. S43
|
artikel
|
| 260 |
P223 The role of psychologist in a cystic fibrosis centre during the COVID-19 pandemic – experience of a Polish paediatric centre
|
Borawska-Kowalczyk, U.
|
|
|
20 |
S1 |
p. S107
|
artikel
|
| 261 |
P122 The role of the clinical pharmacy specialist in monitoring adherence to inhaled therapies in patients with cystic fibrosis in the Republic of North Macedonia
|
Atanasova Nadzinska, M.
|
|
|
20 |
S1 |
p. S76
|
artikel
|
| 262 |
P183 The role of the nutritionist in care of adult patients with cystic fibrosis in Republic of North Macedonia
|
Panovska, S.
|
|
|
20 |
S1 |
p. S94
|
artikel
|
| 263 |
P131 The systemic IgA autoantibody profile of adult cystic fibrosis
|
Tucker, S.
|
|
|
20 |
S1 |
p. S79
|
artikel
|
| 264 |
P061 The UK Clinical Trials Accelerator Platform - a national cystic fibrosis clinical trials network increasing access to clinical trials for the UK cystic fibrosis community
|
Brendell, R.
|
|
|
20 |
S1 |
p. S57
|
artikel
|
| 265 |
P186 The use of recombinant human DNase in a large adult cystic fibrosis centre: a quality improvement review
|
Orr, A.
|
|
|
20 |
S1 |
p. S95-S96
|
artikel
|
| 266 |
P191 The use of technology and web-based exercise programmes to improve engagement and quality of exercise sessions delivered to paediatric inpatients during an admission
|
Day, H.
|
|
|
20 |
S1 |
p. S97
|
artikel
|
| 267 |
P204 The what-if's….considering the psychological impacts of CFTR modulators
|
Puckey, M.
|
|
|
20 |
S1 |
p. S101
|
artikel
|
| 268 |
P049 Tolerance induction (hyposensitisation) in drug intolerance to CFTR modulators
|
Eschenhagen, P.
|
|
|
20 |
S1 |
p. S53
|
artikel
|
| 269 |
P246 Transition in cystic fibrosis: international trends
|
Office, D.
|
|
|
20 |
S1 |
p. S114
|
artikel
|
| 270 |
P233 Treatment outcome preferences among people with cystic fibrosis: a discrete choice experiment
|
Cameron, R.
|
|
|
20 |
S1 |
p. S109-S110
|
artikel
|
| 271 |
P169 Trends in glycaemic control in a cohort of patients with cystic fibrosisrelated diabetes
|
Khanam, R.
|
|
|
20 |
S1 |
p. S90
|
artikel
|
| 272 |
P012 Two-year neonatal screening for cystic fibrosis in Republic of North Macedonia
|
Fustik, S.
|
|
|
20 |
S1 |
p. S42
|
artikel
|
| 273 |
P212 Understanding (the experiences of) how mindfulness is used by people with cystic fibrosis: barriers and enablers
|
Kauser, S.
|
|
|
20 |
S1 |
p. S104
|
artikel
|
| 274 |
P145 Unwanted effects of an essential oil component, citral, on the susceptibility of Pseudomonas aeruginosa to antibiotics
|
Tetard, A.
|
|
|
20 |
S1 |
p. S83
|
artikel
|
| 275 |
P168 Use of faecal elastase in patients with cystic fibrosis and mutation analysis in the Republic of North Macedonia
|
Jakovska Maretti, T.
|
|
|
20 |
S1 |
p. S90
|
artikel
|
| 276 |
P211 Use of telemedicine for mental health screening during the COVID-19 pandemic
|
Bruschwein, H.
|
|
|
20 |
S1 |
p. S103
|
artikel
|
| 277 |
P079 Using a learning health system to understand medicine waste in cystic fibrosis – the Easy Medicines for Burden Reduction And Care Enhancement (EMBRACE) study
|
Bevan, A.
|
|
|
20 |
S1 |
p. S63
|
artikel
|
| 278 |
P235 Using a 1,500-patient learning health system (LHS) to support virtual clinics and medicines optimisation: a UK seven-centre Patient and Public Involvement (PPI) project to understand user experience
|
Dawson, S.
|
|
|
20 |
S1 |
p. S110-S111
|
artikel
|
| 279 |
P195 Using remote access musculoskeletal consultations within a cystic fibrosis specialist physiotherapy service: a pilot
|
Morrison, L.
|
|
|
20 |
S1 |
p. S98
|
artikel
|
| 280 |
P076 Using the Cystic Fibrosis Foundation consensus guidelines to assess the timing of lung transplant referral for individuals with cystic fibrosis in a single large adult UK centre: do they help?
|
Dave, K.
|
|
|
20 |
S1 |
p. S62
|
artikel
|
| 281 |
P102 Utility of Dynamic Chest Radiography (DCR) for calculating lung volume subdivisions in adult people with cystic fibrosis
|
FitzMaurice, T.S.
|
|
|
20 |
S1 |
p. S70
|
artikel
|
| 282 |
P214 Virtual cystic fibrosis doctor: design, development, and user experience pilot study
|
Morrissy, D.
|
|
|
20 |
S1 |
p. S104
|
artikel
|
| 283 |
P256 Waiting for double lung transplantation: psychological impact (review)
|
Havermans, T.
|
|
|
20 |
S1 |
p. S117
|
artikel
|
| 284 |
P164 What is the tolerance of antibiotic dry powder inhalers in patientswith cystic fibrosis?
|
Wilson, P.
|
|
|
20 |
S1 |
p. S89
|
artikel
|
| 285 |
P097 Who's talking about cystic fibrosis? The changing landscape of internet postings related to cystic fibrosis: a two-year comparative study
|
Vagg, T.
|
|
|
20 |
S1 |
p. S68-S69
|
artikel
|
| 286 |
P081 30 years of organisation of care for cystic fibrosis patients in the Russian Federation
|
Kondratyeva, E.
|
|
|
20 |
S1 |
p. S64
|
artikel
|
| 287 |
WS05.2 A combined host- and pathogen-directed therapeutic approach as a novel strategy for the control of multidrug resistant Mycobacterium abscessus infection
|
Poerio, N.
|
|
|
20 |
S1 |
p. S9
|
artikel
|
| 288 |
WS04.1 A comparison of subjective verses objective measures for assessing physical activity in cystic fibrosis: a systematic review
|
Dundas, M.
|
|
|
20 |
S1 |
p. S7
|
artikel
|
| 289 |
WS12.1 An exploratory study to determine the impact of lumacaftor/ivacaftor (LUM/IVA) on disease progression in children 2 through 5 years of age with cystic fibrosis homozygous for F508del-CFTR (F/F)
|
Stahl, M.
|
|
|
20 |
S1 |
p. S22-S23
|
artikel
|
| 290 |
WS08.4 An investigation of the effect of ivacaftor on survival using UK cystic fibrosis Registry data
|
Keogh, R.H.
|
|
|
20 |
S1 |
p. S16
|
artikel
|
| 291 |
WS07.2 A PI3Kγ-peptide promotes Cl− secretion through activation of both CFTR - dependent and independent currents
|
Murabito, A.
|
|
|
20 |
S1 |
p. S13
|
artikel
|
| 292 |
WS07.6 Aquaporin 3 modulates transepithelial fluid resorption upon exposure of airway epithelia to hyperosmotic solutions
|
Sauter, A.
|
|
|
20 |
S1 |
p. S14
|
artikel
|
| 293 |
WS09.6 A randomised clinical trial of antimicrobial duration for treatment of cystic fibrosis pulmonary exacerbations (STOP2)
|
West, N.
|
|
|
20 |
S1 |
p. S18
|
artikel
|
| 294 |
WS08.2 Cancer incidence and prevalence among patients with cystic fibrosis: data from the National French Cystic Fibrosis Registry
|
Rousset-Jablonski, C.
|
|
|
20 |
S1 |
p. S15
|
artikel
|
| 295 |
WS07.1 CFTR proximity profiling in human airway cell models
|
Iazzi, M.
|
|
|
20 |
S1 |
p. S13
|
artikel
|
| 296 |
WS10.1 Change in body mass index of children with cystic fibrosis after a standardised nutritional algorithm – a quality improvement project
|
Yilmaz Yegit, C.
|
|
|
20 |
S1 |
p. S19
|
artikel
|
| 297 |
WS01.5 Characterisation of the response to the innate immune oxidant hypochlorous acid in Pseudomonas aeruginosa cystic fibrosis isolates
|
Spiga, L.
|
|
|
20 |
S1 |
p. S2
|
artikel
|
| 298 |
WS02.1 Cirrhosis with portal hypertension is a risk factor for early mortality in cystic fibrosis patients
|
Pals, F.H.
|
|
|
20 |
S1 |
p. S3
|
artikel
|
| 299 |
WS03.3 Clinical and genetic characteristics of Russian cystic fibrosis patients with the first time described pathogenic variants in the CFTR gene
|
Adyan, T.
|
|
|
20 |
S1 |
p. S6
|
artikel
|
| 300 |
WS09.5 Clinical applications of using drug monitoring for standard caftor regimens
|
Qiu, F.
|
|
|
20 |
S1 |
p. S18
|
artikel
|
| 301 |
WS13.6 Clinical outcomes in patients with cystic fibrosis with Exophiala dermatitidis grown in sputum
|
Tewkesbury, D.
|
|
|
20 |
S1 |
p. S26
|
artikel
|
| 302 |
WS01.1 Commensal bacteria in cystic fibrosis airway infections modulate growth and inflammation of P. aeruginosa
|
Tony-Odigie, A.
|
|
|
20 |
S1 |
p. S1
|
artikel
|
| 303 |
WS10.2 Comparison of food frequency and body composition between cystic fibrosis patients and healthy controls
|
Mielus, M.
|
|
|
20 |
S1 |
p. S19
|
artikel
|
| 304 |
WS06.1 Defining key outcomes to evaluate performance of newborn screening programmes for cystic fibrosis
|
Munck, A.
|
|
|
20 |
S1 |
p. S11
|
artikel
|
| 305 |
WS05.6 Degradation of rhinovirus-induced IL-6 by Pseudomonas aeruginosa in an in vitro model of bacterial-viral coinfection
|
Endres, A.
|
|
|
20 |
S1 |
p. S10
|
artikel
|
| 306 |
WS10.5 Developing a Cystic Fibrosis Mindful Eating Practice (CFMEP) to support healthy eating and weight self-regulation
|
Egan, H.
|
|
|
20 |
S1 |
p. S20
|
artikel
|
| 307 |
WS07.4 Development of a humanised cystic fibrosis mouse model
|
Mottais, A.
|
|
|
20 |
S1 |
p. S14
|
artikel
|
| 308 |
WS05.1 Dynamics of inflammatory mediators during airway infection in cystic fibrosis patients and healthy controls – serial non-invasive upper airway sampling by nasal lavage
|
Erdmann, N.M.
|
|
|
20 |
S1 |
p. S9
|
artikel
|
| 309 |
WS12.3 Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor in cystic fibrosis severe patients with the F508del/minimal function genotype
|
Carnovale, V.
|
|
|
20 |
S1 |
p. S23-S24
|
artikel
|
| 310 |
WS08.3 Effectiveness of the prolonged azithromycin treatment: data from the European Cystic Fibrosis Patient Registry
|
Drevinek, P.
|
|
|
20 |
S1 |
p. S15
|
artikel
|
| 311 |
WS04.6 Effects of a partially supervised conditioning program in cystic fibrosis: an international multi-centre, randomised controlled trial (ACTIVATE-CF)
|
Hebestreit, H.
|
|
|
20 |
S1 |
p. S8
|
artikel
|
| 312 |
WS06.6 Electrical impedance tomography as a clinical monitoring tool for pulmonary exacerbations in cystic fibrosis
|
Folino, A.
|
|
|
20 |
S1 |
p. S12-S13
|
artikel
|
| 313 |
WS09.2 Elexacaftor combinations (partially) restore CFTR function to previously drug-refractory mutations G85E and N1303K
|
Ensinck, M.
|
|
|
20 |
S1 |
p. S17
|
artikel
|
| 314 |
WS01.4 Eradicating Pseudomonas persistence in adult patients with cystic fibrosis with a new algorithm of antibiotic selection
|
Tetz, G.
|
|
|
20 |
S1 |
p. S2
|
artikel
|
| 315 |
WS06.4 βeta-adrenergic sweat test (BAST) in a South African cohort with inconclusive cystic fibrosis diagnosis: a pilot study
|
Zampoli, M.
|
|
|
20 |
S1 |
p. S12
|
artikel
|
| 316 |
WS02.4 Evaluating the role of short chain fatty acids in cystic fibrosis
|
van Dorst, J.
|
|
|
20 |
S1 |
p. S4
|
artikel
|
| 317 |
WS07.5 Evaluation of TMEM16A as a modifier for cystic fibrosis lung phenotype utilising cystic fibrosis patient-specific human-induced pluripotent stem cells
|
Jaboreck, M.-C.
|
|
|
20 |
S1 |
p. S14
|
artikel
|
| 318 |
WS12.2 Evolution of inflammatory parameters during CFTR-modulator therapy with lumacaftor/ivacaftor in children aged 6 to 12 years
|
Rössler, J.
|
|
|
20 |
S1 |
p. S23
|
artikel
|
| 319 |
WS04.4 Exercise testing and training in German cystic fibrosis centres – temporal trends from 2001 to 2019
|
Hebestreit, A.
|
|
|
20 |
S1 |
p. S8
|
artikel
|
| 320 |
WS04.5 Exercise testing using supramaximal verification in cystic fibrosis
|
Williams, C.
|
|
|
20 |
S1 |
p. S8
|
artikel
|
| 321 |
WS14.4 Exploring cystic fibrosis patient and staff perceptions of the Virtual Healthcare Hub during the COVID-19 pandemic at the All Wales Adult Cystic Fibrosis Service
|
Birkin, E.
|
|
|
20 |
S1 |
p. S28
|
artikel
|
| 322 |
WS01.6 Exploring Pseudomonas aeruginosa phage resistance and prevention strategies
|
Vaitekenas, A.
|
|
|
20 |
S1 |
p. S3
|
artikel
|
| 323 |
WS09.1 First results of the HIT-CF ex vivo organoid study show rescue of CFTR with ultra-rare mutations by a novel triple combination of CFTR modulators
|
Silva, I.A.L.
|
|
|
20 |
S1 |
p. S17
|
artikel
|
| 324 |
WS10.6 Food insecurity among the cystic fibrosis population in the United States
|
Seyoum, S.
|
|
|
20 |
S1 |
p. S20
|
artikel
|
| 325 |
WS03.5 Genetic variation of genes for xenobiotic-metabolising enzymes and the risk of nasal polyps development in patients with cystic fibrosis
|
Novoselova, O.
|
|
|
20 |
S1 |
p. S6
|
artikel
|
| 326 |
WS06.3 High-efficient CFTR modulation does not normalise ß-adrenergic sweat secretion rate in cystic fibrosis patients
|
Pallenberg, S.
|
|
|
20 |
S1 |
p. S11-S12
|
artikel
|
| 327 |
WS01.2 Impact of estradiol on Pseudomonas aeruginosa biofilms derived from cystic fibrosis clinical isolates
|
Afzal, F.
|
|
|
20 |
S1 |
p. S1
|
artikel
|
| 328 |
WS08.6 Impact of triple therapy on IVantibiotic requirements in cystic fibrosis: combining evidence from a patient Registry and randomised trials
|
Keogh, R.H.
|
|
|
20 |
S1 |
p. S16-S17
|
artikel
|
| 329 |
WS01.3 Linking CFTR modulators to Pseudomonas aeruginosa infection
|
Cigana, C.
|
|
|
20 |
S1 |
p. S1-S2
|
artikel
|
| 330 |
WS02.3 Liver cirrhosis and transplantation in cystic fibrosis in the Russian Federation
|
Zhekaite, E.
|
|
|
20 |
S1 |
p. S4
|
artikel
|
| 331 |
WS04.3 Lung function as a determinant of the evolution of exercise capacity over a three-year follow-up period in patients with cystic fibrosis
|
Evangelista Campos, N.
|
|
|
20 |
S1 |
p. S7-S8
|
artikel
|
| 332 |
WS12.6 Maternal and foetal outcomes following elexacaftor-tezacaftorivacaftor use during pregnancy and lactation
|
Taylor-Cousar, J.
|
|
|
20 |
S1 |
p. S24
|
artikel
|
| 333 |
WS11.5 Mental health screening as an intervention: how patients and caregivers contribute to improving our processes.
|
Landau, E.
|
|
|
20 |
S1 |
p. S22
|
artikel
|
| 334 |
WS13.2 Metaproteomics profiling of the dynamic of the whole microbial components of the cystic fibrosis lung microbiota during CFTR modulator therapy
|
Hardouin, P.
|
|
|
20 |
S1 |
p. S25
|
artikel
|
| 335 |
WS13.3 Microbiome composition during a personalised internet-supported exercise and nutrition program
|
Knoll, R.L.
|
|
|
20 |
S1 |
p. S25
|
artikel
|
| 336 |
WS13.5 Molecular epidemiology of Mycobacterium abscessus isolates recovered from German cystic fibrosis patients
|
Wetzstein, N.
|
|
|
20 |
S1 |
p. S26
|
artikel
|
| 337 |
WS03.1 New cis-regulatory elements modulate CFTR expression
|
Collobert, M.
|
|
|
20 |
S1 |
p. S5
|
artikel
|
| 338 |
WS03.4 Notable cystic fibrosis cases of Greek-Cypriot originwith rare or unique CFTR genotypes
|
Matthaiou, A.M.
|
|
|
20 |
S1 |
p. S6
|
artikel
|
| 339 |
WS06.2 Nutritional and pulmonary outcomes of cystic fibrosis screen-positive infants with an inconclusive diagnosis
|
Gonska, T.
|
|
|
20 |
S1 |
p. S11
|
artikel
|
| 340 |
WS07.3 Phenotypic and genotypic characterisation of a novel mouse model of F508del-CFTR in genetically diverse collaborative cross
|
Sipione, B.
|
|
|
20 |
S1 |
p. S13
|
artikel
|
| 341 |
WS14.2 Potential factors influencing reduced requirements for intravenous antibiotics during the COVID-19 pandemic
|
Richards, K.
|
|
|
20 |
S1 |
p. S27
|
artikel
|
| 342 |
WS11.3 Predicting anxiety, depression and affectivity in adults living with cystic fibrosis: the role of psychological resilience and self-compassion over a 2-year period
|
Mitmansgruber, H.
|
|
|
20 |
S1 |
p. S21
|
artikel
|
| 343 |
WS08.1 Pregnancy and perinatal outcomes in women with cystic fibrosis in the UK: a population-based study using UK Registry data, 2003–2017
|
Esan, O.B.
|
|
|
20 |
S1 |
p. S15
|
artikel
|
| 344 |
WS05.3 P2X7 receptor inhibition limits inflammatory response of monocytes to LPS and ATP through inflammasome regulation in cystic fibrosis
|
Gabillard-Lefort, C.
|
|
|
20 |
S1 |
p. S9
|
artikel
|
| 345 |
WS11.4 Randomised controlled trial piloting the “Coping and Learning to Manage Stress in CF” (CALM) telehealth intervention to reduce depressive and anxious symptoms in adults with cystic fibrosis
|
Bathgate, C.
|
|
|
20 |
S1 |
p. S21-S22
|
artikel
|
| 346 |
WS13.1 Rare species may act as problem-solvers in critical situations of the bacterial co-occurrence network in cystic fibrosis airways
|
Pust, M.-M.
|
|
|
20 |
S1 |
p. S25
|
artikel
|
| 347 |
WS03.6 Referral pathway to the genetics service for families of paediatric patients newly diagnosed with cystic fibrosis
|
Sadlers, V.
|
|
|
20 |
S1 |
p. S7
|
artikel
|
| 348 |
WS09.3 Rescue of CFTR function in primary bronchial epithelial cells from patients with cystic fibrosis using lipid nanoparticle delivery of RNAbased therapies
|
Torres, M.
|
|
|
20 |
S1 |
p. S17-S18
|
artikel
|
| 349 |
WS02.6 Retinopathy in cystic fibrosis-related diabetes
|
Allen, L.
|
|
|
20 |
S1 |
p. S5
|
artikel
|
| 350 |
WS14.5 SARS-CoV-2 driving rapid change in cystic fibrosis services: the role of the clinical nurse specialist
|
Dunk, R.
|
|
|
20 |
S1 |
p. S28
|
artikel
|
| 351 |
WS10.3 Short-term impact of Kaftrio® onweight and use of pancreatic enzyme replacement therapy
|
Connolly, A.
|
|
|
20 |
S1 |
p. S19
|
artikel
|
| 352 |
WS10.4 Sodium status in patients with cystic fibrosis: how to monitor based on urine sample?
|
Van Biervliet, S.
|
|
|
20 |
S1 |
p. S20
|
artikel
|
| 353 |
WS11.6 Stakeholder input into the development of a cystic fibrosis-specific cognitive-behavioral intervention for adolescents
|
Friedman, D.
|
|
|
20 |
S1 |
p. S22
|
artikel
|
| 354 |
WS12.4 Testicular pain and swelling following elexacaftor/tezacaftor/ivacaftor therapy is associated with epididymal abnormalities
|
Tewkesbury, D.
|
|
|
20 |
S1 |
p. S24
|
artikel
|
| 355 |
WS11.1 The anxiety levels of children with cystic fibrosis and healthy children during the COVID-19 pandemic
|
Ergenekon, A.P.
|
|
|
20 |
S1 |
p. S20-S21
|
artikel
|
| 356 |
WS14.1 The effect of the COVID-19 pandemic on quality of life of adults with cystic fibrosis
|
Birkin, E.
|
|
|
20 |
S1 |
p. S27
|
artikel
|
| 357 |
WS02.5 The insulinogenic index as a predictive marker of cystic fibrosis-related diabetes
|
Poli, P.
|
|
|
20 |
S1 |
p. S4-S5
|
artikel
|
| 358 |
WS09.4 The novel mucolytic agent MUC-031 reduces mucus plugging in mice with cystic fibrosis-like lung disease
|
Addante, A.
|
|
|
20 |
S1 |
p. S18
|
artikel
|
| 359 |
WS11.2 The psychological implications and health risks of cystic fibrosis preand post-CFTR modulator therapy
|
Keyte, R.
|
|
|
20 |
S1 |
p. S21
|
artikel
|
| 360 |
WS02.2 The relationship between genotype and severe hepatic phenotype in cystic fibrosis patients with one F508del CFTR mutation
|
Duursma, S.
|
|
|
20 |
S1 |
p. S3-S4
|
artikel
|
| 361 |
WS05.4 The role of airway epithelial cells in the abnormal biosynthesis of specialised pro-resolving lipid mediators in cystic fibrosis
|
Shum, M.
|
|
|
20 |
S1 |
p. S9-S10
|
artikel
|
| 362 |
WS04.2 To investigate which physical factors influence the cardiorespiratory fitness in paediatric patients with cystic fibrosis who have no ventilatory limitation during exercise (ventilatory reserve ≥15%)
|
Burghard, M.
|
|
|
20 |
S1 |
p. S7
|
artikel
|
| 363 |
WS08.5 Treatment patterns in people with cystic fibrosis: have they changed since the introduction of ivacaftor?
|
Granger, E.
|
|
|
20 |
S1 |
p. S16
|
artikel
|
| 364 |
WS13.4 Unraveling antibiotic resistance mechanisms and dynamics of resistant Staphylococcus aureus isolates during chronic airway infection in cystic fibrosis patients
|
Neumann, C.
|
|
|
20 |
S1 |
p. S26
|
artikel
|
| 365 |
WS05.5 Unravelling the role of IL-17 receptor C during the development of airway chronic infections by Pseudomonas aeruginosa
|
Saliu, F.
|
|
|
20 |
S1 |
p. S10
|
artikel
|
| 366 |
WS12.5 Use of chronic maintenance therapies for cystic fibrosis in patients on elexacaftor/tezacaftor/ivacaftor at a single centre
|
Toporek, A.
|
|
|
20 |
S1 |
p. S24
|
artikel
|
| 367 |
WS06.5 Validation of automated airway-artery method to diagnosis of cystic fibrosis-related bronchiectasis and airway wall thickening
|
Lv, Q.
|
|
|
20 |
S1 |
p. S12
|
artikel
|
| 368 |
WS03.2 Variation in the number of copies of ribosomal genes in the genomes of cystic fibrosis patients
|
Kondratyeva, E.
|
|
|
20 |
S1 |
p. S5
|
artikel
|
| 369 |
WS14.3 Virtual consultation in cystic fibrosis: an Italian experience
|
Carnovale, V.
|
|
|
20 |
S1 |
p. S27-S28
|
artikel
|
| 370 |
WS14.6 Working together, apart: developing a new model for a cystic fibrosis psychology-led virtual support group
|
McKenzie-Howat, E.
|
|
|
20 |
S1 |
p. S28
|
artikel
|
Tijdschrift beschrijving